Holen Sie sich die Stockscreener-App
8.41
1.20%
0.10
Vorhandelsmarkt:
8.27
-0.14
-1.66%
Schlusskurs vom Vortag:
$8.31
Offen:
$8.49
24-Stunden-Volumen:
1.70M
Relative Volume:
0.88
Marktkapitalisierung:
$863.50M
Einnahmen:
$187.64M
Nettoeinkommen (Verlust:
$-95.00M
KGV:
-8.8526
EPS:
-0.95
Netto-Cashflow:
$-69.02M
1W Leistung:
-10.63%
1M Leistung:
+15.21%
6M Leistung:
+21.36%
1J Leistung:
-39.06%
1-Tages-Spanne:
$8.21
$8.595
1-Wochen-Bereich:
$8.21
$9.72
52-Wochen-Spanne:
$5.635
$13.92
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Firmenname
Day One Biopharmaceuticals Inc
Sektor
Branche
Telefon
650 484-0899
Adresse
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Vergleichen Sie DAWN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
8.41 | 853.23M | 187.64M | -95.00M | -69.02M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-09 | Bestätigt | Needham | Buy |
| 2024-08-01 | Hochstufung | BofA Securities | Underperform → Buy |
| 2024-04-24 | Bestätigt | Needham | Buy |
| 2023-04-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-02-08 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-03 | Eingeleitet | Oppenheimer | Perform |
| 2022-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Buy |
| 2022-12-01 | Eingeleitet | BofA Securities | Buy |
Alle ansehen
Day One Biopharmaceuticals Inc Aktie (DAWN) Neueste Nachrichten
How buybacks impact Day One Biopharmaceuticals Inc. stock valueTrade Performance Summary & Verified High Yield Trade Plans - Newser
Day One to buy Mersana Therapeutics for $25/share upfront - MSN
Day One Biopharmaceuticals, Inc. $DAWN Shares Purchased by Geode Capital Management LLC - MarketBeat
Will Day One Biopharmaceuticals Inc. stock deliver shareholder valueJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - Newser
What drives Day One Biopharmaceuticals Inc stock pricePrice Momentum Alerts & Investor Community Interactions - earlytimes.in
(DAWN) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
DAWN CEO moves Day One shares among Bender family trusts - Stock Titan
How Recent Developments Are Shaping the Day One Biopharma Investment Story - Yahoo Finance
HC Wainwright & Co. Reiterates Day One Biopharmaceuticals (DAWN) Buy Recommendation - Nasdaq
DAWN: HC Wainwright & Co. Reaffirms Buy Rating with $25 Target | - GuruFocus
Buy Rating Affirmed for Day One Biopharmaceuticals: Promising FIREFLY-1 Trial Results and Ojemda’s Market Potential - TipRanks
Day One Biopharmaceuticals Announces Three-Year Results from FIREFLY-1 Trial - TradingView
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting - The Manila Times
[8-K] Day One Biopharmaceuticals, Inc. Reports Material Event | DAWN SEC FilingForm 8-K - Stock Titan
Day One Announces Three Year Follow-Up Data From OJEMDA™ - GlobeNewswire
Will Hindalco Industries Limited Stock Benefit From Industry Trends in YEARBearish Engulfing Patterns & Minimize Portfolio Damage with Warnings - earlytimes.in
Is Day One Biopharmaceuticals Inc a good long term investmentRisk Adjusted Returns & High Profit Market Tips - earlytimes.in
Day One Biopharmaceuticals unveils promising Phase 2 trial data - Traders Union
Will Day One Biopharmaceuticals Inc. stock maintain momentum in 2025Trade Analysis Report & Verified Chart Pattern Trade Signals - newser.com
Can Day One Biopharmaceuticals Inc. stock maintain growth trajectoryWeekly Stock Summary & Technical Confirmation Trade Alerts - newser.com
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade - MSN
Can Day One Biopharmaceuticals Inc. stock deliver consistent earnings growthJuly 2025 Breakouts & Real-Time Market Trend Scan - newser.com
Will Day One Biopharmaceuticals Inc. stock recover faster than peersAnalyst Upgrade & Safe Entry Zone Tips - newser.com
Day One Biopharmaceuticals, Inc.Common Stock (NQ: DAWN - Markets Financial Content
Day one biopharma gen counsel sells $38k in shares By Investing.com - Investing.com South Africa
Can Day One Biopharmaceuticals Inc. rally from current levelsQuarterly Trade Review & Free Low Drawdown Momentum Trade Ideas - newser.com
Key resistance and support levels for Day One Biopharmaceuticals Inc.Index Update & Safe Swing Trade Setup Alerts - newser.com
Day One Biopharmaceuticals Inc. stock volume spike explainedTrade Signal Summary & Weekly High Conviction Trade Ideas - newser.com
Day one biopharma gen counsel sells $38k in shares - Investing.com
[Form 4] Day One Biopharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Day One Biopharmaceuticals Executives Sell Shares to Cover Tax Liabilities - TradingView
COO York II Acquires 12,813 Of Day One Biopharmaceuticals Inc [DAWN] - TradingView
Day One Biopharmaceuticals CEO Jeremy Bender Sells Shares - TradingView
What Fibonacci levels say about Day One Biopharmaceuticals Inc. reboundTake Profit & Daily Profit Focused Stock Screening - newser.com
Key deals this week: Merck, Day One Biopharmaceutical, ABN AMRO, Revvity, Centerspace and more - MSN
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Avadel deems Lundbeck offer ‘superior’ to Alkermes’: Deals Report - biocentury.com
Finanzdaten der Day One Biopharmaceuticals Inc-Aktie (DAWN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):